Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALADIN-DAPTCLTI: Duration of DAPT in CLTI After Distal Revascularization
NCT07512960Phase 3Recruiting
- Sponsor
- Fondation Hôpital Saint-Joseph
- Start
- Jun 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing CLOPIDOGREL with PLACEBO CLOPIDOGREL (2 arms). Primary endpoint: Amputation-free survival at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on NCT07512960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512960.